chartexchange

BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair

Newsfile | Oct 14, 2026 8:00 AM EDT

Vancouver, British Columbia--(Newsfile Corp. - October 14, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced the formation of a Scientific Advisory Board ("SAB") to guide the clinical development of BETR-001. Professor Peter Goadsby, MD, PhD, FRS, has been appointed Co-Chair.The SAB will advise the Company's management and Board of...

Read original article